ArticleScientific reports2025
AttBiLSTM_DE: enhancing anticancer peptide prediction using word embedding and an optimized attention-based BiLSTM framework.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer remains a major global health issue, causing numerous deaths annually. Standard treatments like chemotherapy and radiotherapy often exhibit cytotoxic characteristics, harming healthy cells and leading to significant side effects. In this context, anticancer peptides (ACPs) offer a promising strategy by specifically triggering apoptosis in cancer cells while protecting healthy tissues. However, the experimental screening process for new ACPs involves significant costs and requires considerable labor. To address these challenges, we propose an advanced computational framework: AttBiLSTM_DE, which combines an Attention-based Bidirectional LSTM architecture with Optimized Weighted Features for accurate ACP predictions. Firstly, we employed four NLP-based feature encoding techniques: One-Hot Encoding, Global Vectors (GloVe), fastText, and Word2Vec to convert peptide sequences into numerical representations. Additionally, k-mer embedding was used to help the model recognize important subsequence fragments within the sequences. Then, we also developed a stochastic Differential Evolution (DE) algorithm to construct hybrid features, optimize feature weights, and generate the most informative attributes. Finally, the weighted feature sets were analyzed with a Bidirectional LSTM model augmented by an attention mechanism. This bidirectional architecture effectively captures contextual dependencies from both preceding and succeeding peptide sequences, while the attention mechanism emphasizes the most pertinent aspects, thus enhancing the model's prediction performance. Through extensive evaluation, our proposed AttBiLSTM_DE outperformed conventional attention-based deep learning models in predictive performance, achieving an accuracy of 95.85% and an AUC of 98.48%. These impressive results indicate that our AttBiLSTM_DE effectively predicts ACPs and is able to aid in further cancer treatment and drug development. Furthermore, we have developed an online web server to enable real-time prediction based on our proposed model, which is publicly accessible at: https://att-bi-lstm-de-acp.vercel.app/.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.